Incyte Corporation vs NextEra Energy, Inc. — how do they compare? Incyte Corporation trades at $112.75 (market cap $22.99B), while NextEra Energy, Inc. trades at $77.33 (market cap $160.75B). The key difference: NextEra Energy, Inc. is far larger — about 7× Incyte Corporation's market cap, and NextEra Energy, Inc. pays a 3.23% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and NextEra Energy, Inc. for 83 Days on average.
| INCY | NEE | |
|---|---|---|
Market Cap | $22.99B | $160.75B |
Volume | 1,274,487 | 10,598,021 |
Sector | Health | Utilities |
52-Week High | $129.93 | $97.88 |
52-Week Low | $83.80 | $75.49 |
Typical Hold Time | 33 Days | 83 Days |
Enterprise Value | $18.50B | $268.08B |
Dividend Yield | — | 3.23% |
Signals from Pluang's Aura AI — not financial advice
INCY trades at $112.75, up 0.02% on the day, with a bullish technical signal from oscillators but bearish moving averages. The company reported strong Q2 2026 earnings, beating expectations with EPS of $3.09 versus $2.15, and revenue growth from $5.14B in 2025 to a projected $5.8B in 2026. Recent FDA approval for Atebrioz and a strategic push for post-JAKAFI growth highlight pipeline progress. Valuation ratios appear reasonable with a P/E of 14.45 and EV/EBITDA of 8.94.
Outlook is positive with a consensus price target of $132.07, implying 17% upside, supported by 52% analyst buy ratings. Risks include reliance on JAKAFI, which loses exclusivity after 2029, and near-term earnings volatility as seen in the Q4 2025 miss. Strong cash flow and profitability metrics suggest resilience, but execution on pipeline diversification is critical for sustained growth.
NextEra Energy (NEE) trades at $77.06, down 1.05% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals with a 32.4% net income margin and consistent earnings beats in recent quarters, though it missed in Q4 2025. Recent news highlights growth initiatives, including a $22.3 billion energy infrastructure project in Texas announced on September 30, 2026.
The outlook remains positive with a consensus price target of $96.00, implying 25% upside, supported by robust cash flow and profitability. Risks include rising debt levels, with debt-to-asset ratio increasing to 47.6% in 2025, and sensitivity to interest rate changes. Analyst sentiment is bullish with 66.66% buy ratings, but technical weakness near 52-week lows warrants caution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →